Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Antipsychotic-induced weight gain (WG) and metabolic abnormalities are major concerns. This review was untaken to answer if there is a weight-neutral second-generation antipsychotic for bipolar disorder (BPD). Areas covered: English-language literature in MEDLINE was searched with the keywords of antipsychotic/second-generation antipsychotic or generic/brand name of second-generation antipsychotic, and BPD/mania/depression or bipolar maintenance, and safety/tolerability or WG/weight increase, and randomized, placebo-controlled trial. Difference between an antipsychotic monotherapy and placebo in absolute weight gain (AWG) and/or ≥ 7% (WG in three phases of BPD was compared based on the data from original publications. The number needed to treat to harm was used for the comparison of ≥ 7% WG. Among antipsychotics with short-term (mania and/or bipolar depression) and long-term (maintenance) studies, olanzapine, asenapine, quetiapine, risperidone had significant WG compared to placebo in both short-term and long-term trials. Aripiprazole did not cause significant WG compared to placebo in short-term studies, but caused significant WG in long-term studies. Paliperidone-ER-induced WG was significant in a mania study as measured with AWG, and ziprasidone caused significant WG in a mania study measured with ≥ 7% WG. Expert commentary: These data suggest that it is unlikely there is a weight-neutral second-generation antipsychotic in BPD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent reviews further suggest that asenapine and aripiprazole (longer term use) 809 also may lead to weight gain, but the impact of lurasidone on weight is minimal.810”
Citations
Cites
Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322 · cited 1×
“In contrast, patients in depressive phase may gain weight from the beginning due to lack of activity, endocrine changes, and other factors [63,64].”
BackgroundTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationCalabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Self-citationOlanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559
Self-citationTohen, M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539
Keck, P. E., Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A., Ingenito, G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
Young, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & EMBOLDEN I (Trial 001) Investigators (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04995gre · Cited by 390
(2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0219 · Cited by 383
Research works printed but not linked: 3
- Lipkovich I, 2009, Psychopharmacol Bull, 42, 23
- Gao K, Milestones in drug therapy series (M Parnham, J Bruinvels, series eds), bipolar depression: molecular neurobiology, clinical diagnosis, and pharmacotherapy
- Gao K, 2015, Neurosci, 31, 572
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationVieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Self-citationDouble-blind, placebo-controlled trial of pioglitazone for bipolar depression
Aftab, A., Kemp, D. E., Ganocy, S. J., Schinagle, M., Conroy, C. M., Brownrigg, B., D’Arcangelo, N., Goto, T., Woods, N., Serrano, M. B., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.090 · Cited by 45
Self-citationGao, K., Fang, F., Wang, Z., & Calabrese, J. R. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000596 · Cited by 21
Self-citationYaramala, S. R., McElroy, S. L., Geske, J. R., Winham, S. J., Gao, K., Reilly-Harrington, N. A., Ketter, T. A., Deckersbach, T., Kinrys, G., Kamali, M., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.025 · Cited by 23
Self-citation
Metadata
- Authors
- Fang, F., Wang, Z., Wu, R., Calabrese, J. R., & Gao, K.
- Affiliations
- Shanghai Mental Health Center (CN)
- Central South University (CN)
- University Hospitals of Cleveland (US)
- Corresponding author
- Wang, Zuowei
- Gao, Keming
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2017-01-02
- Volume
- 17
- Issue
- 4
- Pages
- 407-418
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2564477552
- Cited by
- 18
- References
- 67
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 1
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Neurotherapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81301159)
- Shanghai Key Medicine Specialties Program (ZK2012A12)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bipolar disorder, atypical antipsychotics, antipsychotic-induced weight gain, aripiprazole, olanzapine, asenapine, quetiapine, risperidone, ziprasidone, metabolic side effects, mania, bipolar depression
- MeSH terms
- Olanzapine, Benzodiazepines, Bipolar Disorder, Humans, Antipsychotic Agents, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder? https://app.cochat.ai/papers/10.1080/14737175.2016.1276284
- The paper
- Fang, F., Wang, Z., Wu, R., Calabrese, J. R., & Gao, K. (2017). Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder? Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2016.1276284
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.